Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.04
NYSE:BSX's Cash to Debt is ranked lower than
96% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NYSE:BSX: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BSX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.13 Max: 0.69
Current: 0.04
0.03
0.69
Equity to Asset 0.37
NYSE:BSX's Equity to Asset is ranked lower than
80% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:BSX: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BSX' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.49 Max: 0.57
Current: 0.37
0.21
0.57
Interest Coverage 1.91
NYSE:BSX's Interest Coverage is ranked lower than
94% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. NYSE:BSX: 1.91 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 3.22
Current: 1.91
0.37
3.22
F-Score: 7
Z-Score: 1.68
M-Score: -2.40
WACC vs ROIC
8.27%
5.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.33
NYSE:BSX's Operating margin (%) is ranked higher than
59% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NYSE:BSX: 5.33 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BSX' s Operating margin (%) Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 11.86
Current: 5.33
-53.36
11.86
Net-margin (%) 4.14
NYSE:BSX's Net-margin (%) is ranked higher than
59% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. NYSE:BSX: 4.14 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BSX' s Net-margin (%) Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 5.79
Current: 4.14
-56.12
5.79
ROE (%) 5.39
NYSE:BSX's ROE (%) is ranked higher than
59% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. NYSE:BSX: 5.39 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BSX' s ROE (%) Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 5.39
Current: 5.39
-44.65
5.39
ROA (%) 1.94
NYSE:BSX's ROA (%) is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. NYSE:BSX: 1.94 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BSX' s ROA (%) Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 2.03
Current: 1.94
-21.16
2.03
ROC (Joel Greenblatt) (%) 22.96
NYSE:BSX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. NYSE:BSX: 22.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BSX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 32.39
Current: 22.96
-144.7
32.39
Revenue Growth (3Y)(%) 4.60
NYSE:BSX's Revenue Growth (3Y)(%) is ranked higher than
53% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. NYSE:BSX: 4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BSX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 2.7 Max: 28.7
Current: 4.6
-10.5
28.7
EBITDA Growth (3Y)(%) 5.60
NYSE:BSX's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. NYSE:BSX: 5.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BSX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.1  Med: 4.5 Max: 271.1
Current: 5.6
-71.1
271.1
GuruFocus has detected 3 Warning Signs with Boston Scientific Corp $NYSE:BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BSX Guru Trades in Q1 2016

John Paulson 74,000 sh (New)
Steven Cohen 2,665,600 sh (+286.15%)
Diamond Hill Capital 20,339,317 sh (+3.77%)
Pioneer Investments 3,787,109 sh (+3.24%)
PRIMECAP Management 43,354,400 sh (+0.02%)
Eaton Vance Worldwide Health Sciences Fund 3,450,000 sh (unchged)
Alan Fournier Sold Out
Vanguard Health Care Fund 63,222,390 sh (-1.38%)
Mario Gabelli 796,046 sh (-3.13%)
Dodge & Cox 427,430 sh (-5.19%)
Michael Price 1,740,000 sh (-12.12%)
Ray Dalio 36,184 sh (-59.01%)
Jim Simons 618,405 sh (-82.19%)
» More
Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Eaton Vance Worldwide Health Sciences Fund 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%)
» More
Q4 2016

BSX Guru Trades in Q4 2016

Joel Greenblatt 99,384 sh (New)
David Tepper 550,000 sh (New)
Ray Dalio 91,000 sh (+78.78%)
Jim Simons 2,625,305 sh (+39.35%)
Pioneer Investments 1,941,017 sh (+3.31%)
Diamond Hill Capital 3,351,408 sh (+1.87%)
PRIMECAP Management 41,920,457 sh (+0.28%)
Michael Price 700,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 371,671 sh (-2.74%)
Mario Gabelli 653,146 sh (-2.96%)
Vanguard Health Care Fund 43,872,669 sh (-5.69%)
John Paulson 288,000 sh (-29.76%)
Steven Cohen 358,400 sh (-77.91%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:SYK, NYSE:EW, OTCPK:SNNUF, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, NYSE:VAR, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:CNVVY, NAS:ABMD, NAS:MASI, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAY, NAS:IART, OTCPK:GGNDF » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws in manufacturing and sterilization processes.

Top Ranked Articles about Boston Scientific Corp

Diamond Hill Buys Ford, Sells Boston Scientific Firm's largest 2nd quarter trades
Diamond Hill Capital (Trades, Portfolio) Management Inc. was established in 2000 and is a registered investment adviser based in Columbus, Ohio. During the second quarter, the firm traded the following stocks. Read more...
Michael Price Trims Boston Scientific, Buys Outerwall The guru's largest trades of 2nd quarter
Michael Price (Trades, Portfolio) is the 271st richest person in the world, according to Forbes. A renowned money manager, he learned finance as a $200-a-week research assistant under Max Heine. The following are his largest trades of the second quarter: Read more...
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Guru exited position in Pfizer in 2nd quarter
Seven of Vanguard Health Care Fund (Trades, Portfolio)’s top 10 second-quarter transactions were divestitures or reductions, including its most noteworthy deal of the quarter. Read more...
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Recent insider sells from company CEOs
According to GuruFocus Insider Data, these are the largest CEO sells during the past week: Gilead Sciences Inc., Boston Scientific Corp., Sonic Corp. and HealthEquity Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 96.79
BSX's P/E(ttm) is ranked lower than
88% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. BSX: 96.79 )
Ranked among companies with meaningful P/E(ttm) only.
BSX' s P/E(ttm) Range Over the Past 10 Years
Min: 13.87  Med: 30.86 Max: 404.33
Current: 96.79
13.87
404.33
Forward P/E 20.24
BSX's Forward P/E is ranked higher than
62% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. BSX: 20.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 96.79
BSX's PE(NRI) is ranked lower than
90% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. BSX: 96.79 )
Ranked among companies with meaningful PE(NRI) only.
BSX' s PE(NRI) Range Over the Past 10 Years
Min: 13.87  Med: 30.86 Max: 404.33
Current: 96.79
13.87
404.33
Price/Owner Earnings (ttm) 51.50
BSX's Price/Owner Earnings (ttm) is ranked lower than
73% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. BSX: 51.50 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BSX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.58  Med: 43.27 Max: 936
Current: 51.5
11.58
936
P/B 5.10
BSX's P/B is ranked lower than
70% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. BSX: 5.10 )
Ranked among companies with meaningful P/B only.
BSX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 1.39 Max: 5.3
Current: 5.1
0.59
5.3
P/S 4.13
BSX's P/S is ranked lower than
63% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. BSX: 4.13 )
Ranked among companies with meaningful P/S only.
BSX' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 2.21 Max: 4.18
Current: 4.13
1.02
4.18
PFCF 114.39
BSX's PFCF is ranked lower than
91% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. BSX: 114.39 )
Ranked among companies with meaningful PFCF only.
BSX' s PFCF Range Over the Past 10 Years
Min: 7.26  Med: 20.45 Max: 220
Current: 114.39
7.26
220
POCF 67.50
BSX's POCF is ranked lower than
90% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. BSX: 67.50 )
Ranked among companies with meaningful POCF only.
BSX' s POCF Range Over the Past 10 Years
Min: 5.79  Med: 15.75 Max: 68.55
Current: 67.5
5.79
68.55
EV-to-EBIT 96.27
BSX's EV-to-EBIT is ranked lower than
93% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. BSX: 96.27 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -4.1 Max: 25784.2
Current: 96.27
-2577.3
25784.2
EV-to-EBITDA 41.41
BSX's EV-to-EBITDA is ranked lower than
85% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. BSX: 41.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.4 Max: 241.8
Current: 41.41
-680.1
241.8
Current Ratio 0.90
BSX's Current Ratio is ranked lower than
90% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. BSX: 0.90 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.37 Max: 1.94
Current: 0.9
0.78
1.94
Quick Ratio 0.64
BSX's Quick Ratio is ranked lower than
89% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. BSX: 0.64 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.09 Max: 1.67
Current: 0.64
0.5
1.67
Days Inventory 149.67
BSX's Days Inventory is ranked lower than
58% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. BSX: 149.67 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 149.67
113.61
164.78
Days Sales Outstanding 64.07
BSX's Days Sales Outstanding is ranked higher than
54% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. BSX: 64.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 64.07
58.51
66.79
Days Payable 67.28
BSX's Days Payable is ranked higher than
56% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. BSX: 67.28 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 67.28
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.3  Med: -0.7 Max: 4.6
Current: -1
-22.3
4.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.85
BSX's Price/Projected FCF is ranked lower than
63% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. BSX: 2.85 )
Ranked among companies with meaningful Price/Projected FCF only.
BSX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.47 Max: 4.27
Current: 2.85
0.52
4.27
Price/Median PS Value 1.86
BSX's Price/Median PS Value is ranked lower than
87% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. BSX: 1.86 )
Ranked among companies with meaningful Price/Median PS Value only.
BSX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.32 Max: 4.02
Current: 1.86
0.48
4.02
Price/Peter Lynch Fair Value 1.42
BSX's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. BSX: 1.42 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BSX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 1.42 Max: 2.88
Current: 1.42
0
2.88
Earnings Yield (Greenblatt) (%) 0.99
BSX's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. BSX: 0.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 2.8 Max: 9.1
Current: 0.99
0.5
9.1
Forward Rate of Return (Yacktman) (%) 42.06
BSX's Forward Rate of Return (Yacktman) (%) is ranked higher than
96% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. BSX: 42.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 43
Current: 42.06
3.1
43

More Statistics

Revenue (TTM) (Mil) $8,386
EPS (TTM) $ 0.26
Beta0.85
Short Percentage of Float1.57%
52-Week Range $16.82 - 25.65
Shares Outstanding (Mil)1,362.10

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,820 9,404 10,070
EPS ($) 1.25 1.41 1.62
EPS w/o NRI ($) 1.25 1.41 1.62
EPS Growth Rate
(3Y to 5Y Estimate)
17.11%
Dividends Per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
John Paulson Continues to Buy These 8 Stocks Dec 23 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Michael Price Sells Dolby Labs, EMC Nov 21 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
Michael Price Trims Boston Scientific, Buys Outerwall Aug 23 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 

More From Other Websites
Edwards' 'Restart' On CardiAQ Heart-Valve Sets Up 2018 Europe Launch: RBC Feb 21 2017
U.S. top court rejects Boston Scientific's patent licensing appeal Feb 21 2017
U.S. Supreme Court rejects Boston Scientific's patent licensing appeal Feb 21 2017
Boston Scientific to Participate in Cowen and Company 37th Annual Healthcare Conference Feb 21 2017
Boston Scientific to Participate in 2017 RBC Capital Markets Global Healthcare Conference Feb 15 2017
BOSTON SCIENTIFIC CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Feb 10 2017
Executives Find This Toy Maker’s Shares Attractive After Stock Price Plunges, Plus Other Insider... Feb 09 2017
Post Earnings Coverage as Stryker's Revenue Gained 16.7% on Constant Currency Basis; Adjusted EPS... Feb 07 2017
ETFs with exposure to Boston Scientific Corp. : February 6, 2017 Feb 06 2017
Boston Scientific Corp. :BSX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 Feb 06 2017
Boston Scientific Corp. :BSX-US: Earnings Analysis: 2016 By the Numbers : February 3, 2017 Feb 03 2017
Boston Scientific Corp. :BSX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 3, 2017 Feb 03 2017
No "Sophomore Slump" Ahead For Boston Scientific Feb 02 2017
Why the state's two biggest medical device firms have gained $4.5B in market cap this week Feb 02 2017
Edited Transcript of BSX earnings conference call or presentation 2-Feb-17 1:00pm GMT Feb 02 2017
Edwards Lifesciences Sinks 9%; Is This A Buying Opportunity? Feb 02 2017
Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View Feb 02 2017
Boston Scientific beats Street 4Q forecasts Feb 02 2017
Boston Scientific beats Street 4Q forecasts Feb 02 2017
Boston Scientific (BSX) Beats on Earnings & Revenues in Q4 Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)